Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

532
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
532
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

611
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
611
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

223
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
223

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evaluation of Electrical Impedance Myography as a Noninvasive Musculoskeletal Biomarker in Infantile- and Late-Onset Pompe Disease.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

At-Home Versus in-Clinic Vital Capacity Measurement: Insights From the HEALEY ALS Platform Trial.

Muscle & nerve·2026
Same author

Evaluating the interpretability of clinical speech AI models: Lessons from two user studies.

Computer speech & language·2026
Same author

Evaluation of Digital Technologies for Home-Based Assessment in People With Amyotrophic Lateral Sclerosis.

Annals of clinical and translational neurology·2026
Same author

An End-to-End Overview of Clinical Speech AI.

IEEE transactions on audio, speech, and language processing (2025)·2026
Same author

Safety and Efficacy of PrimeC in Amyotrophic Lateral Sclerosis: The PARADIGM Randomized Clinical Trial.

JAMA neurology·2026

Related Experiment Video

Updated: Jul 26, 2025

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

34.9K

A speech-based prognostic model for dysarthria progression in ALS.

Gabriela Stegmann1,2, Sherman Charles2,3, Julie Liss1,2

  • 1Arizona State University, Phoenix, AZ, United States.

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
|June 13, 2023
PubMed
Summary

This study predicts Amyotrophic Lateral Sclerosis (ALS) speech impairment using articulatory precision from speech recordings. The model accurately forecasts future speech decline in ALS patients.

Keywords:
Prognosisamyotrophic lateral sclerosis (ALS)articulatory precisionlongitudinalspeech

More Related Videos

Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing
07:22

Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing

Published on: December 1, 2023

578
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

31.9K

Related Experiment Videos

Last Updated: Jul 26, 2025

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS
12:43

A Protocol for Comprehensive Assessment of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis ALS

Published on: February 21, 2011

34.9K
Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing
07:22

Minimally Invasive Murine Laryngoscopy for Close-Up Imaging of Laryngeal Motion During Breathing and Swallowing

Published on: December 1, 2023

578
Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

31.9K

Area of Science:

  • Neurology
  • Speech-Language Pathology
  • Biomedical Engineering

Background:

  • Amyotrophic Lateral Sclerosis (ALS) progressively impacts speech, affecting patient communication and quality of life.
  • Accurate prediction of speech impairment is crucial for timely interventions and patient management in ALS.
  • Existing methods for assessing speech decline in ALS may lack the granularity for precise, individualized forecasting.

Purpose of the Study:

  • To develop and validate a prognostic model for predicting future speech impairment in ALS patients.
  • To establish the clinical utility of measuring articulatory precision from speech recordings for ALS progression monitoring.
  • To correlate acoustic measures of speech with established clinical scales like the ALSFRS-R speech subscore.

Main Methods:

  • Utilized longitudinal speech recordings and ALSFRS-R speech subscores from two ALS studies.
  • Developed an algorithm to quantify articulatory precision by analyzing phoneme acoustics in speech samples.
  • Validated the articulatory precision measure against perceptual ratings and used it to build a predictive model for future speech capabilities.

Main Results:

  • Established strong analytical and clinical validity for articulatory precision (r = .9 with perceptual ratings).
  • Successfully predicted articulatory precision 30-90 days ahead using a 45-90 day calibration period.
  • Achieved low mean absolute errors: 4% for articulatory precision and 14% for ALSFRS-R speech subscores.

Conclusions:

  • A subject-specific prognostic model accurately predicts future articulatory precision in ALS patients.
  • The model effectively forecasts ALSFRS-R speech subscores, offering a valuable tool for clinical assessment.
  • This approach enables precise, data-driven prediction of speech decline in individuals with ALS.